296.1000 6.75 (2.33%)
NSE Mar 13, 2026 15:46 PM
Volume: 1.6M
 

296.10
2.33%
Business Line
The progress India has made in terms of building the capabilities and number of scientists work in its favour.Also, India has a much better regulatory record than how it was perceived about 7 and 8 years ago': Suven Pharma's Executive Chairman Vivek Sharma
Cohance Lifesciences.. has an average target of 527.00 from 2 brokers.
More from Cohance Lifesciences Ltd.
Recommended